CD274 and non-small cell lung carcinoma: In addition, treatment with pembrolizumab (anti-PD-1) is also approved for patients with non-small-cell lung cancer (NSCLC) who have high PD-L1 expression on tumor cells (at least 50% of tumor cells for first-line use).